These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1230 related articles for article (PubMed ID: 7921967)

  • 1. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 2. T cells take aim at cancer.
    Pardoll D
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
    [No Abstract]   [Full Text] [Related]  

  • 3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.
    Nakamura Y; Wakimoto H; Abe J; Kanegae Y; Saito I; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1994 Nov; 54(22):5757-60. PubMed ID: 7525049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetically engineered T cells as adoptive immunotherapy of cancer.
    Ma Q; Gonzalo-Daganzo RM; Junghans RP
    Cancer Chemother Biol Response Modif; 2002; 20():315-41. PubMed ID: 12703212
    [No Abstract]   [Full Text] [Related]  

  • 7. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.
    Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH
    Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular immunotherapy of cancer].
    Kawakami Y
    Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
    [No Abstract]   [Full Text] [Related]  

  • 13. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies.
    Yamaguchi Y; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Miyahara E; Toge T
    Hum Cell; 2003 Dec; 16(4):183-9. PubMed ID: 15147038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous activated lymphocyte therapy in a community hospital.
    Horváth J; Szabó-Szabari M; Sinkovics JG
    Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 62.